INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $257,000 | -14.0% | 2,000 | 0.0% | 0.13% | -13.8% |
| Q4 2015 | $299,000 | +9.1% | 2,000 | +21.2% | 0.15% | -9.5% |
| Q3 2015 | $274,000 | -25.5% | 1,650 | +8.2% | 0.17% | -27.3% |
| Q2 2015 | $368,000 | -8.5% | 1,525 | +7.0% | 0.23% | -12.5% |
| Q1 2015 | $402,000 | – | 1,425 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |